Comparative Pharmacology
Head-to-head clinical analysis: VARIBAR PUDDING versus VISIPAQUE 270.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VARIBAR PUDDING versus VISIPAQUE 270.
VARIBAR PUDDING vs VISIPAQUE 270
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barium sulfate acts as a radiopaque contrast agent. It has high atomic number (z=56) and density, which attenuates X-rays and provides positive contrast in the gastrointestinal tract. It is not absorbed systemically and coats the mucosal surface, allowing visualization of luminal anatomy and pathology.
Iodinated radiocontrast agent; attenuates X-rays, providing vascular and tissue opacification.
125 mL orally once for upper GI studies; 250-500 mL orally once for small bowel follow-through. Not for IV use.
Intraarterial or intravenous administration; dose depends on procedure, age, weight, cardiac output, and clinical condition. Typical adult dose: 50-150 mL of 270 mg I/mL (50-80 mL for coronary arteriography, 30-50 mL for left ventriculography; up to 250 mL total for multiple injections).
None Documented
None Documented
Not applicable; barium sulfate is not absorbed systemically; gastrointestinal transit time is approximately 1–2 hours for gastric emptying and 6–24 hours for colonic passage.
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function (creatinine clearance >60 mL/min). Prolonged in renal impairment, correlating with degree of kidney dysfunction.
Varibar (barium sulfate) is not absorbed from the GI tract; it is excreted unchanged in feces. 100% fecal elimination as unabsorbed barium sulfate.
Renal excretion via glomerular filtration; >95% of administered dose eliminated unchanged in urine within 24 hours. Minimal biliary or fecal excretion (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent